Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor plus FLAG-Ida in Relapsed or Refractory AML
NCT03661515Phase 1Completed
- Sponsor
- Fundación PETHEMA
- Start
- Jul 2018
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of selinexor in acute myeloid leukemia (AML), sponsored by Fundación PETHEMA. Primary endpoints: Maximum Tolerated Dose at 56 days and Recommended Phase 2 Dose at 3 months. Started Jul 2018; status: completed.
02
Drugs
selinexor
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03661515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03661515.